We serve Chemical Name:1-piperidin-4-yl-3H-indol-2-one,hydrochloride CAS:58562-44-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-piperidin-4-yl-3H-indol-2-one,hydrochloride
CAS.NO:58562-44-0
Synonyms:1-piperidin-4-yl-3H-indol-2-one,hydrochloride
Molecular Formula:C13H17ClN2O
Molecular Weight:252.74000
HS Code:2933790090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:441.5ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:32.34000
Exact Mass:252.10300
LogP:2.52350
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-piperidin-4-yl-3H-indol-2-one,hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-piperidin-4-yl-3H-indol-2-one,hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-piperidin-4-yl-3H-indol-2-one,hydrochloride Use and application,1-piperidin-4-yl-3H-indol-2-one,hydrochloride technical grade,usp/ep/jp grade.
Related News: The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%. 1-piperidin-4-yl-3H-indol-2-one,hydrochloride manufacturer The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%. 1-piperidin-4-yl-3H-indol-2-one,hydrochloride supplier For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” 1-piperidin-4-yl-3H-indol-2-one,hydrochloride vendor In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase. 1-piperidin-4-yl-3H-indol-2-one,hydrochloride factory For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.”
